Selective serotonin reuptake inhibitors and adverse pregnancy outcomes

American Journal of Obstetrics and Gynecology

Volumn 194, Issue 4, 2006, Pages 961-966

  Wen, Shi Wu ^a,b   Yang, Qiuying ^a,b,c   Garner, Peter ^f   Fraser, William ^d   Olatunbosun, Olufemi ^e   Nimrod, Carl ^a,b   Walker, Mark ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f NONE

Author keywords

Birth defect; Depression; Fetal death; Fetus; Low birth weight; Pregnancy; Preterm birth; Seizure; Serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DELIVERY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FETUS DEATH; GESTATION PERIOD; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE;

ADULT; COHORT STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 33645866176     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.02.019     Document Type: Article

References (28)

1. O'Hara M.W., Neunaber D.J., and Zekoski E.M. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol 93 (1984) 158-171
2. Barron W.M., and Lindheimer M.D. Preface and guidelines for prescribing drugs to pregnant women. In: Barron W.M., and Lindheimer M.D. (Eds). Medical disorders during pregnancy (1991), Mosby-Year Book, St. Louis (MO) IX-XII
3. Burbui C., Guaiana G., and Hotopf M. Amitriptyline for in patients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry 37 (2004) 93-97
4. Fergusson D., Doucette S., Glass K.C., Shapiro S., Healy D., Hebert P., et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 330 (2005) 396-412
5. Hardman J., and Limbird L. Goodman and Gilman's: the pharmacological basis of therapeutics. 9th ed. (1996), McGraw Hill, New York p. 445-6
6. Koren G., Matsui D., Einarson A., Knoppert D., and Steiner M. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?. CMAJ 172 (2005) 1457-1459
7. Chambers C.D., Johnson K.A., Dick L.N., Felix R.J., and Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335 (1996) 1010-1015
8. Nordeng H., Lindemann R., Perminov K.V., and Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 90 (2001) 288-291
9. Sanz E.J., De-las-Cuevas C., Kiuru A., Bate A., and Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365 (2005) 451-453
10. Zeskind P.S., and Stephens L.E. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113 (2004) 368-375
11. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142 (2003) 402-408
12. Laine K., Heikkinen T., Ekblad U., and Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatr 60 (2003) 720-726
13. Kulin N.A., Pastuszak A., Sage S.R., Schick-Boschetto B., Spirey G., Feldkamp M., et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multi-center study. JAMA 279 (1998) 609-610
14. Nulman I., Rovert J., Stewart D., Wolpin J., Gradner H.A., Theis J.G., et al., for the Motherisk Program, Hospital for Sick Children and University of Toronto. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336 (1997) 258-262
15. Pastuszak A., Schick-Boschetto B., and Zuber C. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269 (1993) 2246-2248
16. Hendrick V., Smith L., Suri R., Hwang S., Haynes D., and Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188 (2003) 812-815
17. Hallberg P., and Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 25 (2005) 59-73
18. Downey W., Beck P., McNutt M., Stang M.R., Osei W., and Nichol J. Health databases in Saskatchewan. In: Strom B.L. (Ed). Pharmacoepidemiology. 3rd ed. (2000), Wiley, Chichester, UK 325-345
19. Commission on Professional and Hospital Activities. International classification of disease, 9th revision: clinical modification (1992), The Commission, Ann Arbor (MI)
20. Canadian classification of diagnostic, therapeutic, and surgical procedures. Ottawa, Ontario (1986), Statistics Canada, Canada
21. Rothman K.J., and Greenland S. Modern epidemiology. 2nd ed. (1998), Lippincott Raven, Philadelphia
22. West S.L., Richter A., Melfi C.A., McNutt M., Nennstiel M.E., and Mauskopf J.A. Assessing the Saskatchewan database for outcomes research studies of depression and its treatment. J Clin Epidemiol 53 (2000) 823-831
23. De Jong van den Berg L.T., Feenstra N., Sorensen H.T., and Cornel M.C. Improvement of drug exposure data in a registration of congenital anomalies: pilot-study, pharmacist and mother as sources for drug exposure data during pregnancy. Teratology 60 (1999) 33-36
24. Lattimore K.A., Donn S.M., Kaciroti N., Kemper A.R., Neal Jr. C.R., and Vazquez D.M. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 25 (2005) 595-604
25. Wogelius P., Norgaard M., and Mutt Munk E. Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcomes. Pharmacoepidemiology and Drug Safety 14 (2005) S143
26. Alwan S., Polifka J.E., and Friedman J.M. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73 (2005) 123-130
27. Bjoro K., and Stray-Pedersen S. In vitro perfusion studies on human umbilical arteries: I, vasoactive effects of serotonin, PGF2α and PGE2. Acta Obstet Gynecol Scand 65 (1986) 351-355
28. Haugen G. The vasoactive effects of serotonin in normal and single umbilical artery cords in normotensive and hypertensive pregnancies. Hypertens Pregnancy 15 (1996) 39-50